Freedom Capital analyst Ilya Zubkov downgraded Johnson & Johnson to Hold from Buy with a price target of $190, up from $180. While stating that J&J “once again” exceeded both the firm’s expectations and market consensus with its “robust” Q3 results and noting that the company raised its revenue guidance for the third time this year, the firm is downgrading shares as the stock is now trading near its fair value estimate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Bicara sinks after J&J reports head and neck cancer data
- Activist Jana Partners Takes Stake in Cooper Companies, Presses for Strategic Review
- Johnson & Johnson announces new results from Phase 1b/2 OrigAMI-4 study
- Kenvue Stock (KVUE) Plunges on Legal Woes Related to Talc Products